<DOC>
	<DOC>NCT01856439</DOC>
	<brief_summary>The study is designed to assess the long term tolerability of ProSavin and whether it is safe and efficacious in patients administered ProSavin from the PS1/001/07 study .</brief_summary>
	<brief_title>Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>must have met all inclusion criteria for study PS1/001/07 willing to have LDOPA dosage reduced/withdrawn at the discretion of the investigator at regular intervals to allow assessment of ProSavin in the absence of concomitant antiparkinsonian medication. affiliated with the French social security health care system (Patients enrolled in France only) signed and dated written informed consent obtained from the patient and/or the patient's legally acceptable representative, if applicable, in accordance with the local regulations must have been treated with ProSavin/Sham</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>ProSavin</keyword>
	<keyword>Gene therapy</keyword>
</DOC>